H M Horlings - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

H M Horlings

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Breast Cancer Research : BCR|June 19, 2023

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancerM C Liefaard, A van der Voort, M S van Ramshorst, et al.

Human Reproduction (Oxford, England)|November 15, 2018

Iatrogenic endometriosis harbors somatic cancer-driver mutationsV Lac, L Verhoef, R Aguirre-Hernandez, et al.

Nature Communications|April 14, 2025

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trialS L Aronson, B Thijssen, M Lopez-Yurda, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Breast Cancer Research : BCR|June 19, 2023

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancerM C Liefaard, A van der Voort, M S van Ramshorst, et al.

Human Reproduction (Oxford, England)|November 15, 2018

Iatrogenic endometriosis harbors somatic cancer-driver mutationsV Lac, L Verhoef, R Aguirre-Hernandez, et al.

Nature Communications|April 14, 2025

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trialS L Aronson, B Thijssen, M Lopez-Yurda, et al.

Pageof 2